Affiliation:
1. Redx Pharma, Alderley Park, Cheshire, United Kingdom
Abstract
ABSTRACT
The novel bacterial topoisomerase inhibitor class is an investigational type of antibacterial inhibitor of DNA gyrase and topoisomerase IV that does not have cross-resistance with the quinolones. Here, we report the evaluation of the
in vitro
properties of a new series of this type of small molecule. Exemplar compounds selectively and potently inhibited the catalytic activities of
Escherichia coli
DNA gyrase and topoisomerase IV but did not block the DNA breakage-reunion step. Compounds showed broad-spectrum inhibitory activity against a wide range of Gram-positive and Gram-negative pathogens, including biodefence microorganisms and
Mycobacterium tuberculosis
. No cross-resistance with fluoroquinolone-resistant
Staphylococcus aureus
and
E. coli
isolates was observed. Measured MIC
90
values were 4 and 8 μg/ml against a panel of contemporary multidrug-resistant isolates of
Acinetobacter baumannii
and
E. coli
, respectively. In addition, representative compounds exhibited greater antibacterial potency than the quinolones against obligate anaerobic species. Spontaneous mutation rates were low, with frequencies of resistance typically <10
−8
against
E. coli
and
A. baumannii
at concentrations equivalent to 4-fold the MIC. Compound-resistant
E. coli
mutants that were isolated following serial passage were characterized by whole-genome sequencing and carried a single Arg38Leu amino acid substitution in the GyrA subunit of DNA gyrase. Preliminary
in vitro
safety data indicate that the series shows a promising therapeutic index and potential for low human ether-a-go-go-related gene (hERG) inhibition (50% inhibitory concentration [IC
50
], >100 μM). In summary, the compounds' distinct mechanism of action relative to the fluoroquinolones, whole-cell potency, low potential for resistance development, and favorable
in vitro
safety profile warrant their continued investigation as potential broad-spectrum antibacterial agents.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献